CAR T-cell Therapy Articles

Kite Reports Cerebral Edema Death in ZUMA-1 CAR T-Cell Trial
The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.
Juno Hopes to Cut Production of CAR T Cells to Just 2 Days
JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR  T cells from weeks to just 2 days.
Neelapu Hopeful FDA Will Approve Axicabtagene Ciloleucel for NHL
Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL
Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
Kite Unveils Novel BCMA-Directed CAR T-cell Therapy
A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.
CAR T-Cell Therapy Shows Potential in Head and Neck Cancer
Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.
Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL
Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.
Expert Summarizes State of CAR T-Cell Therapy in Hematologic Malignancies
Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies
CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response
The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.
CAR T-Cell Response Rate Tops 80% in NHL Trial
Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.
Publication Bottom Border
Border Publication